Skip Navigation



British Medical Bulletin Advance Access published online on September 11, 2006
British Medical Bulletin, doi:10.1093/bmb/ldl005
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
77-78/1/23    most recent
ldl005v2
ldl005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Aschan, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aschan, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press. For Permissions, please email: journals.permissions@oxfordjournals.org

Allogeneic haematopoietic stem cell transplantation: current status and future outlook

Johan Aschan

Center for Allogeneic Stem Cell Transplantation and Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden

Correspondence to: Johan Aschan, Department of Medicine, M54, Karolinska University Hospital Huddinge, SE-141 86 Stockholm, Sweden. Tel.: +46 8 585 800 00; fax: +46 8 774 87 25; e-mail: johan.aschan{at}karolinska.se

Allogeneic haematopoietic stem cell transplantation (allo-SCT) is an established treatment of haematological malignancies and other immunohaematopoietic disorders. The use of unrelated donors and cord blood (CB) grafts has increased the possibilities of finding a donor, and results are approaching those after sibling donor transplants. The use of peripheral blood stem cells (PBSCs), instead of bone marrow, results in faster engraftment and increased risk of chronic graft-versus-host disease (GVHD). High-dose myeloablative (MA) conditioning is recently challenged by reduced-intensity conditioning (RIC) for older patients and those with comorbidity. Better diagnostic tools and novel anti-microbial drugs have reduced morbidity and mortality from infections. A major problem is disease relapse. Early detection of minimal residual disease or recurrent recipient haematopoietic cells allows early intervention with immunotherapy. Donor lymphocyte infusions (DLIs) have not only an anti-leukaemic effect but also an anti-tumour effect against a variety of solid organ tumours. New indications such as metastatic solid tumours are investigated. Mesenchymal stem cells (MSC) may enhance engraftment and have immunomodulatory effects.

Keywords: allogeneic haematopoietic stem cell transplantation • unrelated donors • peripheral blood stem cells • leukaemia • reduced-intensity conditioning • graft-versus-host disease • relapse


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.